Actelion Pharmaceuticals Ltd

act-179811 - cadazolid

 

Study ID Status Type Title
AC-061A201 Completed Results Summary A multi-center, double-blind, randomized, active reference, parallel group study to evaluate the efficacy, safety and tolerability of a 10-day twice daily oral administration of three doses of cadazolid (ACT-179811) in subjects with Clostridium difficile associated diarrhea (CDAD)
AC-061A302 Completed Results Summary A multi-center, randomized, double-blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD).